Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases

Clinical Biochemistry

Volumn 48, Issue 9, 2015, Pages 562-568

  Berezin, Alexander ^a   Zulli, Anthony ^b   Kerrigan, Steve ^c   Petrovic, Daniel ^d   Kruzliak, Peter ^e  

^a ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

^b VICTORIA UNIVERSITY   (Australia)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Cardiovascular diseases; Endothelial derived microparticles; Metabolic diseases; Risk stratification

Indexed keywords

BIOLOGICAL MARKER;

AGE; ANGIOGENESIS; ATRIAL FIBRILLATION; BIOLOGICAL ACTIVITY; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; ENDOTHELIAL MICROPARTICLE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIMIT OF DETECTION; METABOLIC DISORDER; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; MEMBRANE MICROPARTICLE; METABOLIC SYNDROME X; PHYSIOLOGY;

BIOMARKERS; CARDIOVASCULAR DISEASES; CELL-DERIVED MICROPARTICLES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC SYNDROME X; RISK ASSESSMENT;

EID: 84929963340     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.02.003     Document Type: Review

References (89)

1. Yusuf S., Rangarajan S., Teo K., Islam S., Li W., Liu L., et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2014, 371(9):818-827.
2. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Executive summary: heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014, 129(3):399-410.
3. Heidenreich P.A., Albert N.M., Allen L.A., Bluemke D.A., Butler J., Fonarow G.C., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013, 6(3):606-619.
4. Huffman M.D., Lloyd-Jones D.M., Ning H., Labarthe D.R., Guzman Castillo M., O'Flaherty M., et al. Quantifying options for reducing coronary heart disease mortality by 2020. Circulation 2013, 127(25):2477-2484.
5. Reyes-Soffer G., Holleran S., Di Tullio M.R., Homma S., Boden-Albala B., Ramakrishnan R., et al. Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism 2010, 59(9):1365-1371.
6. Ehrlich J.R., Kaluzny M., Baumann S., Lehmann R., Hohnloser S.H. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol 2011, 100(11):1029-1036.
7. Shaw A., Doherty M.K., Mutch N.J., MacRury S.M., Megson I.L. Endothelial cell oxidative stress in diabetes: a key driver of cardiovascular complications?. Biochem Soc Trans 2014, 42(4):928-933.
8. Lee P.S., Poh K.K. Endothelial progenitor cells in cardiovascular diseases. World J Stem Cells 2014, 6(3):355-366.
9. Mause S.F., Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010, 107:1047-1057.
10. Arraud N., Linares R., Tan S., Gounou C., Pasquet J.M., Mornet S., et al. Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. J Thromb Haemost 2014, 12(5):614-627.
11. Pirro M., Schillaci G., Bagaglia F., Menecali C., Paltriccia R., Mannarino M.R., et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis 2008, 197(2):757-767.
12. Abid Hussein M.N., Böing A.N., Sturk A., Hau C.M., Nieuwland R. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost 2007, 98:1096-1107.
13. Jimenez J.J., Jy W., Mauro L.M., Soderland C., Horstman L.L., Ahn Y.S. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003, 109:175-180.
14. Pérez-Casal M., Downey C., Cutillas-Moreno B., Zuzel M., Fukudome K., Toh C.H. Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects. Haematologica 2009, 94:387-394.
15. Sabatier F., Roux V., Anfosso F., Camoin L., Sampol J., Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002, 99:3962-3970.
16. Nomura S., Ozaki Y., Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008, 123:8-23.
17. Leroyer A.S., Anfosso F., Lacroix R., Sabatier F., Simoncini S., Njock S.M., et al. Endothelial-derived microparticles: biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost 2010, 104:456-463.
18. Jansen F., Yang X., Franklin B.S., Hoelscher M., Schmitz T., Bedorf J., et al. High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. Cardiovasc Res 2013, 98(1):94-106.
19. Biro E., Nieuwland R., Sturk A. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004, 2:1843-1844.
20. Boyle L.J., Credeur D.P., Jenkins N.T., Padilla J., Leidy H.J., Thyfault J.P., et al. Impact of reduced daily physical activity on conduit artery flow-mediated dilation and circulating endothelial microparticles. J Appl Physiol 2013, 115(10):1519-1525.
21. Boulanger C.M., Leroyer A.S., Amabile N., Tedgui A. Circulating endothelial microparticles: a new marker of vascular injury. Ann Cardiol Angeiol (Paris) 2008, 57:149-154.
22. Spencer D.M., Mobarrez F., Wallén H., Pisetsky D.S. The expression of HMGB1 on microparticles from Jurkat and HL-60 cells undergoing apoptosis in vitro. Scand J Immunol 2014, 80(2):101-110.
23. Winner M., Koong A.C., Rendon B.E., Zundel W., Mitchell R.A. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res 2007, 67(1):186-193.
24. Mezentsev A., Merks R.M., O'Riordan E., Chen J., Mendelev N., Goligorsky M.S., et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol 2005, 289(3):H1106-H1114.
25. Faille D., El-Assaad F., Mitchell A.J., Alessi M.C., Chimini G., Fusai T., et al. Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. J Cell Mol Med 2012, 16(8):1731-1738.
26. Enjeti A.K., Lincz L.F., Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008, 34(7):683-691.
27. Aoki M., Kanamori M., Ohmori K., Takaishi M., Huh N.H., Nogami S., et al. Expression of developmentally regulated endothelial cell locus 1 was induced by tumor-derived factors including VEGF. Biochem Biophys Res Commun 2005, 333(3):990-995.
28. Lee S.K., Yang S.H., Kwon I., Lee O.H., Heo J.H. Role of tumour necrosis factor receptor-1 and nuclear factor-κB in production of TNF-α-induced pro-inflammatory microparticles in endothelial cells. Thromb Haemost Jul 10 2014, 112(3). [Epub ahead of print].
29. Spencer D.M., Gauley J., Pisetsky D.S. The properties of microparticles from RAW 264.7 macrophage cells undergoing in vitro activation or apoptosis. Innate Immun 2014, 20(3):239-248.
30. Densmore J.C., Signorino P.R., Ou J., Hatoum O.A., Rowe J.J., Shi Y., et al. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock 2006, 26:464-471.
31. Meziani F., Tesse A., Andriantsitohaina R. Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol Rep 2008, 60:75-84.
32. Morel O., Toti F., Freyssinet J.M. Markers of thrombotic disease: procoagulant microparticles. Ann Pharm Fr 2007, 65(2):75-84.
33. Loyer X., Vion A.C., Tedgui A., Boulanger C.M. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res 2014, 114(2):345-353.
34. Mastronardi M.L., Mostefai H.A., Soleti R., Agouni A., Martinez M.C., Andriantsitohaina R. Microparticles from apoptotic monocytes enhance nitrosative stress in human endothelial cells. Fundam Clin Pharmacol 2011, 25:653-660.
35. Morel O., Toti F., Bakouboula B., Grunebaum L., Freyssinet J.M. Procoagulant microparticles: 'criminal partners' in atherothrombosis and deleterious cellular exchanges. Pathophysiol Haemost Thromb 2006, 35(1-2):15-22.
36. VanWijk M.J., VanBavel E., Sturk A., Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003, 59(2):277-287.
37. MacKman N., Davis G.E. Blood coagulation and blood vessel development: is tissue factor the missing link?. Arterioscler Thromb Vasc Biol 2011, 31(11):2364-2366.
38. Martinez M.C., Andriantsitohaina R. Microparticles in angiogenesis: therapeutic potential. Circ Res 2011, 109(1):110-119.
39. Peterson D.B., Sander T., Kaul S., et al. Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles. Proteomics 2008, 8(12):2430-2446.
40. Philippova M., Suter Y., Toggweiler S., Schoenenberger A.W., Joshi M.B., Kyriakakis E., et al. T-cadherin is present on endothelial microparticles and is elevated in plasma in early atherosclerosis. Eur Heart J 2011, 32(6):760-771.
41. Brodsky S.V., Malinowski K., Golightly M., Jesty J., Goligorsky M.S. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 2002, 106(18):2372-2378.
42. Markiewicz M., Richard E., Marks N., Ludwicka-Bradley A. Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases. J Aging Res 2013, 2013:734509.
43. Chironi G.N., Boulanger C.M., Simon A., Dignat-George F., Freyssinet J.M., Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res 2009, 335:143-151.
44. Harrison M., Murphy R.P., O'Connor P.L., O'Gorman D.J., McCaffrey N., Cummins P.M., et al. The endothelial microparticle response to a high fat meal is not attenuated by prior exercise. Eur J Appl Physiol 2009, 106(4):555-562.
45. Buzas E.I., György B., Nagy G., Falus A., Gay S. Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol 2014, 10(6):356-364.
46. Faure V., Dou L., Sabatier F., Cerini C., Sampol J., Berland Y., et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost 2006, 4:566-573.
47. Agouni A., Andriantsitohaina R., Martinez M.C. Microparticles as biomarkers of vascular dysfunction in metabolic syndrome and its individual components. Curr Vasc Pharmacol 2014, 12(3):483-492.
48. Lacroix R., Judicone C., Mooberry M., Boucekine M., Key N.S., Dignat-George F., et al. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost Apr 2 2013, [Epub ahead of print]. 10.1111/jth.12207.
49. Gieseler F., Gamperl H., Theophil F., Stenzel I., Quecke T., Ungefroren H., et al. Using annexin V-coated magnetic beads to capture active tissue factor-bearing microparticles from body fluids. Cell Biol Int 2014, 38(2):277-281.
50. Yong P.J., Koh C.H., Shim W. Endothelial microparticles: missing link in endothelial dysfunction?. Eur J Prev Cardiol 2013, 20(3):496-512.
51. Burger D., Montezano A.C., Nishigaki N., He Y., Carter A., Touyz R.M. Endothelial microparticle formation by angiotensin II is mediated via angiotensin II receptor type I/NADPH oxidase/rho kinase pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol 2011, 31(8):1898-1907.
52. Owens A.P., MacKman N. Microparticles in hemostasis and thrombosis. Circ Res 2011, 108(10):1284-1297.
53. Tramontano A.F., Lyubarova R., Tsiakos J., Palaia T., Deleon J.R., Ragolia L. Circulating endothelial microparticles in diabetes mellitus. Mediators Inflamm 2010, 2010:250476.
54. Horstman L.L., Jy W., Jimenez J.J., Ahn Y.S. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004, 9:1118-1135.
55. Rautou P.E., Leroyer A.S., Ramkhelawon B., Devue C., Duflaut D., Vion A.C., et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res 2011, 108(3):335-343.
56. Curtis A.M., Wilkinson P.F., Gui M., Gales T.L., Hu E., Edelberg J.M. p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles. J Thromb Haemost 2009, 7(4):701-709.
57. Wang J., Chen S., Ma X., Cheng C., Xiao X., Chen J., et al. Effects of endothelial progenitor cell-derived microvesicles on hypoxia/reoxygenation-induced endothelial dysfunction and apoptosis. Oxid Med Cell Longev 2013, 2013:572729.
58. Cimmino G., Golino P., Badimon J.J. Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?. Intern Emerg Med 2011, 6(1):29-34.
59. Geddings J.E., Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014, 111(4):570-574.
60. Sarlon-Bartoli G., Bennis Y., Lacroix R., Piercecchi-Marti M.D., Bartoli M.A., Arnaud L., et al. Plasmatic level of leukocyte-derived microparticles is associated with unstable plaque in asymptomatic patients with high-grade carotid stenosis. J Am Coll Cardiol 2013, 62(16):1436-1441.
61. Rautou P.-E., Vion A.-C., Amabile N., Chironi G., Simon A., Tedgui A., et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011, 109:593-606.
62. Jansen F., Yang X., Hoelscher M., Cattelan A., Schmitz T., Proebsting S., et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 2013, 128(18):2026-2038.
63. Jung C., Sörensson P., Saleh N., Arheden H., Rydén L., Pernow J. Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Atherosclerosis 2012, 221(1):226-231.
64. Cui Y., Zheng L., Jiang M., Jia R., Zhang X., Quan Q., et al. Circulating microparticles in patients with coronary heart disease and its correlation with interleukin-6 and C-reactive protein. Mol Biol Rep 2013, 40(11):6437-6442.
65. Montoro-García S., Shantsila E., Tapp L.D., López-Cuenca A., Romero A.I., Hernández-Romero D., et al. Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes. Atherosclerosis 2013, 227(2):313-322.
66. Fan Y., Wang L., Li Y., Yin Z., Xu Z., Wang C. Quantification of endothelial microparticles on modified cytometric bead assay and prognosis in chest pain patients. Circ J 2014, 78(1):206-214.
67. Huang P.H., Huang S.S., Chen Y.H., Lin C.P., Chiang K.H., Chen J.S., et al. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens 2010, 28(8):1655-1665.
68. Hsu C.Y., Huang P.H., Chiang C.H., Leu H.B., Huang C.C., Chen J.W., et al. Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients. PLoS One 2013, 8(7):e68644.
69. Jenkins N.T., Padilla J., Boyle L.J., Credeur D.P., Laughlin M.H., Fadel P.J. Disturbed blood flow acutely induces activation and apoptosis of the human vascular endothelium. Hypertension 2013, 61(3):615-621.
70. Jesel L., Abbas M., Toti F., Cohen A., Arentz T., Morel O. Microparticles in atrial fibrillation: a link between cell activation or apoptosis, tissue remodelling and thrombogenicity. Int J Cardiol 2013, 168(2):660-669.
71. Urschel K., Cicha I., Daniel W.G., Garlichs C.D. Shear stress patterns affect the secreted chemokine profile in endothelial cells. Clin Hemorheol Microcirc 2012, 50(1-2):143-152.
72. Ci H.B., Ou Z.J., Chang F.J., Liu D.H., He G.W., Xu Z., et al. Endothelial microparticles increase in mitral valve disease and impair mitral valve endothelial function. Am J Physiol Endocrinol Metab 2013, 304(7):E695-E702.
73. Rajendran P., Rengarajan T., Thangavel J., Nishigaki Y., Sakthisekaran D., Sethi G., et al. The vascular endothelium and human diseases. Int J Biol Sci 2013, 9(10):1057-1069.
74. Matsuzawa Y., Sugiyama S., Sumida H., Sugamura K., Nozaki T., Ohba K., et al. Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc 2013, 2(6):e000426.
75. Berezin A.E., Kremzer A.A., Samura T.A., Martovitskaya Y.V., Malinovskiy Y.V., Oleshko S.V., et al. Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients. J Cardiol Aug 7 2014, [pii: S0914-5087(14)00200-7, [Epub ahead of print]]. 10.1016/j.jjcc.2014.06.014.
76. Heathfield S.K., Parker B., Zeef L.A., Bruce I.N., Alexander M.Y. Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clin Exp Rheumatol 2013, 31:225-233.
77. Maisel A. Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J Am Coll Cardiol 2011, 58(18):1890-1892.
78. Romanens M., Ackermann F., Sudano I., Szucs T., Spence J.D. Arterial age as a substitute for chronological age in the AGLA risk function could improve coronary risk prediction. Swiss Med Wkly 2014, 144:w13967.
79. Allan G.M., Garrison S., McCormack J. Comparison of cardiovascular disease risk calculators. Curr Opin Lipidol 2014, 25(4):254-265.
80. Ravera M., Cannavò R., Noberasco G., Guasconi A., Cabib U., Pieracci L., et al. High performance of a risk calculator that includes renal function in predicting mortality of hypertensive patients in clinical application. J Hypertens 2014, 32(6):1245-1254.
81. Nelson M.R., Doust J.A. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies. Med J Aust 2013, 198(11):606-610.
82. Chyu J., Fonarow G.C., Tseng C.H., Horwich T.B. Four-variable risk model in men and women with heart failure. Circ Heart Fail 2014, 7(1):88-95.
83. Alba A.C., Agoritsas T., Jankowski M., Courvoisier D., Walter S.D., Guyatt G.H., et al. Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail 2013, 6(5):881-889.
84. Oremus M., Don-Wauchope A., McKelvie R., Santaguida P.L., Hill S., Balion D., et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev 2014, 19(4):471-505.
85. Carrasco-Sanchez F.J., Pez-Rubio M.I. Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing. Mol Diagn Ther 2014, 18(6):599-604.
86. Tushuizen M.E., Diamant M., Sturk A., Nieuwland R. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe?. Arterioscler Thromb Vasc Biol 2011 Jan, 31(1):4-9.
87. Berezin A.E., Kremzer A.A., Samura T.A., MartovitskayaYuV Circulating endothelial-derived apoptotic microparticles in the patients with ischemic symptomatic chronic heart failure: relevance of pro-inflammatory activation and outcomes. Int Cardiovasc Res J 2014, 8(3):116-123.
88. Berezin A.E., Kremzer A.A., Martovitskaya Y.V., Samura T.A., Berezina T.A. The biomarker risk prediction score in chronic heart failure. J Dis Markers 2014, 1(1):8.
89. Canellini G., Rubin O., Delobel J., Crettaz D., Lion N., Tissot J.D. Red blood cell microparticles and blood group antigens: an analysis by flow cytometry. Blood Transfus 2012, 10:39-45.